DISCO Pharmaceuticals and Amgen Ink Exclusive License Deal to Advance Surfaceome-Targeted Cancer Therapies

German biotech DISCO Pharmaceuticals has entered an exclusive license agreement with US biopharma giant Amgen to advance therapeutic programs directed at a cancer cell surface target identified by DISCO’s proprietary surfaceome-mapping technology. Under the agreement with undisclosed upfront payment, Amgen obtains exclusive global rights to develop and commercialize programs directed against the surfaceome target mapped by DISCO, while DISCO stands to receive up to $618 million in aggregate payments and future royalties tied to development and commercial milestones.

The Cologne-based pharmaceutical research company expects that the proceeds of the licensing deal will enable them to advance multiple lead antibody-drug conjugate (ADC) candidates in small cell lung cancer (SCLC) and microsatellite-stable colorectal cancer (MSS-CRC) toward IND-enabling studies and expand its pipeline.

What DISCO’s Platform Brings to the Table

The surfaceome (or cell surface proteome) refers to the complete set of proteins located on the outer surface (plasma membrane) of a cell that are exposed to the extracellular environment. These proteins act as receptors, transporters, enzymes, and structural components involved in cell communication, immune response, and the regulation of transport across the cell membrane, thus playing the “gatekeeping roles” for various vital cellular processes.

DISCO’s value proposition rests on a surfaceome mapping platform that combines cell-surface proteomics with advanced protein-community mapping to identify previously inaccessible target pairs and surface-bound protein communities. This pioneering approach is designed to reveal indication-specific and pan-tumor opportunities that are difficult to detect with conventional target-discovery methods, and to guide the design of bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) with high specificity. From the company’s perspective, the deal is a validation that surfaceome mapping can uncover clinically actionable cell-surface targets suitable for next-generation therapeutic modalities.

DISCO’s Pipeline Focus and Near-term R&D Priorities

DISCO currently focuses its internal pipeline on hard-to-treat solid tumors including SCLC and MSS-CRC, and the company says its first ADC programs are advancing toward the clinic. The license to Amgen pertains to a different, platform-derived target mapped on the cancer surfaceome. The current agreement gives Amgen the right to progress programs against that target through clinical development and commercialization. 

For this reason, the transaction represents both a near-term validation event for DISCO’s discovery capabilities and a pathway to leverage Amgen’s development resources and global commercialization infrastructure for specific assets. “Joining forces with a recognized global leader in advancing innovative cancer treatments underscores the potential inherent in our technology to go beyond traditional cancer targets to deliver novel impactful medicines for high need cancer indications,” said DISCO’s CBO Ajla Hrle.

Strategic Rationale for Amgen and Implications for DISCO

For Amgen, the deal is consistent with an established external innovation strategy: licensing differentiated discovery platforms or early-stage assets that fill gaps in its oncology portfolio. Surfaceome-guided targets and bispecific modalities remain an active area of interest for large oncology developers because of their potential to improve therapeutic index and tumor selectivity. 

For DISCO, partnering with a large, experienced oncology developer accelerates the probability that a platform-derived discovery can reach patients, while allowing DISCO to capture upside via milestones and royalties without bearing the full cost of late-stage development. According to Mark Manfredi, Ph.D., DISCO’s newly-appointed CEO, this agreement “demonstrates the potential of our surfaceome mapping platform technology to uncover cancer cell surface targets with meaningful clinical potential.” He also expressed his optimism that the collaboration with Amgen will enable the company to translate their biological insights into innovative therapies which may deliver better outcomes for patients.

Dr. Manfredi’s remarks reflect continuity with the strategy he outlined upon his CEO appointment and the company’s latest €36 million seed financing round, which aims to advance the DISCO’s lead ADC candidates toward IND-enabling studies.

Scientific and Commercial Context: Why Surfaceome Discovery Matters

Target discovery that focuses on the surfaceome has gained traction because it directly supports modalities that need extracellular access (ADCs, bispecific antibodies, TCEs). By mapping the composition and communities of proteins on the tumor cell surface, companies aim to identify target combinations that improve tumor selectivity or enable novel mechanisms such as conditional activation. 

If DISCO’s platform consistently yields targets with robust biology and acceptable safety windows, the model of early discovery followed by out-licensing to a development partner could be a repeatable commercialization route. That potential explains why Amgen, a company with deep expertise in both antibody therapeutics and late-stage development, would take an exclusive license rather than relying solely on internal discovery.

Author

Richard Chau

Related Post

Markets & Deals

Sino Biopharmaceutical Enters Exclusive Global Licensing Agreement with Sanofi for First-in-Class JAK/ROCK Inhibitor Rovadicitinib

2026-03-04

Prime

[Illustrations] Selective Capital, Targeted Deals, and a Tightened Public-Market Bar: How 2026 Is Shaping M&A and IPOs

2026-02-09

Prime

[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms

2026-02-05